Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
10.57
USD
|
+4.40%
|
|
+9.19%
|
+72.71%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
330
|
1,499
|
1,050
|
389.2
|
139.2
|
273.8
|
-
|
-
|
Enterprise Value (EV)
1 |
330
|
1,499
|
1,050
|
389.2
|
139.2
|
273.8
|
273.8
|
273.8
|
P/E ratio
|
-2.73
x
|
-8.27
x
|
-3.44
x
|
-1.33
x
|
-1
x
|
-2.74
x
|
-3.5
x
|
-28.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
80.3
x
|
202
x
|
592
x
|
37.9
x
|
167
x
|
453
x
|
34.1
x
|
2.61
x
|
EV / Revenue
|
80.3
x
|
202
x
|
592
x
|
37.9
x
|
167
x
|
453
x
|
34.1
x
|
2.61
x
|
EV / EBITDA
|
-
|
-
|
-3,526,960
x
|
-1,477,500
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-4.84
x
|
-1.79
x
|
-1.12
x
|
-3.15
x
|
-3.6
x
|
-4.8
x
|
FCF Yield
|
-
|
-
|
-20.7%
|
-55.8%
|
-89.6%
|
-31.8%
|
-27.8%
|
-20.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,334
|
14,117
|
17,532
|
20,791
|
22,749
|
25,907
|
-
|
-
|
Reference price
2 |
39.60
|
106.2
|
59.88
|
18.72
|
6.120
|
10.57
|
10.57
|
10.57
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/1/22
|
3/1/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.112
|
7.411
|
1.775
|
10.26
|
0.832
|
0.6042
|
8.033
|
104.9
|
EBITDA
|
-
|
-
|
-297.7
|
-263.4
|
-
|
-
|
-
|
-
|
EBIT
1 |
-111.1
|
-124.1
|
-301.2
|
-267.6
|
-143.9
|
-109.9
|
-104.6
|
-23.55
|
Operating Margin
|
-2,702.1%
|
-1,674.25%
|
-16,972.32%
|
-2,607.35%
|
-17,300.28%
|
-18,186.98%
|
-1,302.36%
|
-22.45%
|
Earnings before Tax (EBT)
1 |
-120.8
|
-162.9
|
-303.2
|
-277.7
|
-135.1
|
-102.1
|
-100.1
|
-18.77
|
Net income
1 |
-119.4
|
-166.4
|
-303.7
|
-279.8
|
-135.1
|
-99.42
|
-93.39
|
-18.77
|
Net margin
|
-2,902.75%
|
-2,245.39%
|
-17,109.85%
|
-2,726.67%
|
-16,239.87%
|
-16,454.88%
|
-1,162.55%
|
-17.9%
|
EPS
2 |
-14.52
|
-12.84
|
-17.40
|
-14.04
|
-6.090
|
-3.852
|
-3.020
|
-0.3767
|
Free Cash Flow
1 |
-
|
-
|
-216.9
|
-217.2
|
-124.7
|
-87
|
-76
|
-57
|
FCF margin
|
-
|
-
|
-12,223.6%
|
-2,116.34%
|
-14,986.17%
|
-14,399.21%
|
-946.11%
|
-54.35%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/1/22
|
3/1/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.2917
|
0.8391
|
0.1991
|
0.7844
|
9.154
|
0.1247
|
0.1149
|
0.226
|
0.3884
|
0.1026
|
0.1508
|
0.151
|
0.1512
|
0.1514
|
EBITDA
|
-59.09
|
-104.4
|
-
|
-103.1
|
-34.73
|
-54.95
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-59.95
|
-105.5
|
-71.73
|
-104.1
|
-35.76
|
-55.95
|
-43.95
|
-37.04
|
-35.55
|
-27.39
|
-27.64
|
-27.03
|
-27.8
|
-27.41
|
Operating Margin
|
-20,553.02%
|
-12,573.69%
|
-36,034.06%
|
-13,276.05%
|
-390.61%
|
-44,875.4%
|
-38,239.24%
|
-16,392.04%
|
-9,152.53%
|
-26,686.55%
|
-18,330.24%
|
-17,901.99%
|
-18,384.76%
|
-18,107%
|
Earnings before Tax (EBT)
1 |
-60.17
|
-106.9
|
-79.07
|
-108.5
|
-37.78
|
-54.46
|
-40.65
|
-35.53
|
-33.93
|
-25
|
-25.79
|
-24.96
|
-25.96
|
-25.43
|
Net income
1 |
-60.17
|
-106.9
|
-79.07
|
-108.5
|
-37.78
|
-54.46
|
-40.65
|
-35.53
|
-33.93
|
-25
|
-24.3
|
-23.66
|
-24.18
|
-23.84
|
Net margin
|
-20,627.03%
|
-12,745.21%
|
-39,721.57%
|
-13,831.89%
|
-412.75%
|
-43,685.84%
|
-35,365.69%
|
-15,725.33%
|
-8,734.68%
|
-24,358.15%
|
-16,113.23%
|
-15,666.23%
|
-15,994.54%
|
-15,744.39%
|
EPS
2 |
-3.480
|
-6.000
|
-4.320
|
-5.520
|
-1.800
|
-2.640
|
-1.920
|
-1.560
|
-1.560
|
-5.670
|
-1.004
|
-0.9640
|
-0.9560
|
-0.9320
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/1/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/1/23
|
5/10/23
|
8/9/23
|
11/9/23
|
3/6/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-217
|
-217
|
-125
|
-87
|
-76
|
-57
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-70.6%
|
-90%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-12.40
|
-10.90
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
1.23
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
69.36%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/1/22
|
3/1/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
10.57
USD Average target price
19.25
USD Spread / Average Target +82.12% Consensus |
1st Jan change
|
Capi.
|
---|
| +72.71% | 274M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|